Embryonic stem cell trial back on

Nearly a year after the US Food and Drug Administration placed a hold on the first clinical trial of human embryonic stem cells, the company linkurl:Geron;http://www.geron.com/ has been cleared to continue its study of spinal cord injury, linkurl:it announced today;http://www.geron.com/media/pressview.aspx?id=1229 (July 30). Human embryonic stem cellsImage: Wikimedia commons, Nissim Benvenisty"We are pleased with the FDA's decision to allow our planned clinical trial of GRNOPC1 in spinal cord

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Nearly a year after the US Food and Drug Administration placed a hold on the first clinical trial of human embryonic stem cells, the company linkurl:Geron;http://www.geron.com/ has been cleared to continue its study of spinal cord injury, linkurl:it announced today;http://www.geron.com/media/pressview.aspx?id=1229 (July 30).
Human embryonic stem cells
Image: Wikimedia commons,
Nissim Benvenisty
"We are pleased with the FDA's decision to allow our planned clinical trial of GRNOPC1 in spinal cord injury to proceed," Geron's president and CEO Thomas Okarma said in a statement. The Phase I trial, which aims to use human ESC-derived progenitors of neural support tissue to treat patients with severe spinal cord injury, was to be the first-ever clinical trial of a hESC-based therapy when it was cleared by the FDA in January 2009. That August, however, before any patients had received treatment, the FDA linkurl:placed a hold;http://www.the-scientist.com/blog/display/55898/ on the trial after linkurl:cysts appeared;http://www.the-scientist.com/blog/display/55950/ in some of the animals given the treatment in a preclinical study. Since then, Geron completed an additional preclinical animal study to test new markers and assays, according to today's announcement. After submitting these results to the FDA, the hold was lifted, and the company has been cleared to begin administering the treatment to human patients. "Our goals for the application of GRNOPC1 in subacute spinal cord injury are unchanged," Okarma said -- "to achieve restoration of spinal cord function by the injection of hESC-derived oligodendrocyte progenitor cells directly into the lesion site of the patient's injured spinal cord."
**__Related stories:__***linkurl:Geron trial may resume next year;http://www.the-scientist.com/blog/display/56126/
[30th October 2009]*linkurl:Cysts stall stem cell trial?;http://www.the-scientist.com/blog/display/55950/
[27th August 2009]*linkurl:Human stem cell trial on hold;http://www.the-scientist.com/blog/display/55898/
[20th August 2009]*linkurl:FDA OKs stem cell trial;http://www.the-scientist.com/blog/display/55353/
[23rd January 2009]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Jef Akst

    Jef Akst was managing editor of The Scientist, where she started as an intern in 2009 after receiving a master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses.
Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

fujirebio-square-logo

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours